Welcome to Foundation Medicine

Foundation Medicine is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.

Our portfolio of genomic profiling services

High-quality portfolio

Foundation Medicine: An established portfolio of services for patients across diverse clinical situations

Foundation Medicine’s established portfolio of comprehensive genomic profiling (CGP) services should be used to inform the use of immunotherapies, identify alternative therapy options or identify trial opportunities:1–9
T i s s u e s a m p l e T i s s u e - b a s e d t e s t f o r h a e m a t o l o g i c a l m a l i g n a n c i e s a n d s a r c o m a s 9 , 1 2 HEME E X P L O R E E X P L O R E Solid tumour W h a t type of tumour d o e s y o u r p a t i e n t h a v e ? T i s s u e sample Blood sample T i s s u e - b a s e d t e s t f o r s o l i d t u m o u r s 1 L i q u i d b i o p s y t e s t f o r s o l i d t u m o u r s 8 , 1 1
All our services use our leading comprehensive genomic profiling approach to identify clinically relevant alterations and potentially expand treatment options

All of Foundation Medicine’s services use our CGP approach, which analyses the tumour genome to identify clinically relevant alterations and inform treatment decision-making.1–9
Genomic database


Our tests evolve as our understanding of cancer broadens

Our continuously growing genomic database currently includes over 400,000 genomic profiles across numerous tumour subtypes.12 Advanced bioinformatics interrogate the data, including fields not currently reported clinically (such as loss of heterozygosity), to generate potentially actionable insights.12

Our growing database includes 200,000+ genomic profiles, allowing our tests to constantly evolve so we can provide the most clinically relevant insights

CGP: comprehensive genomic profiling; FFPE: formalin-fixed paraffin embedded.

M-GB-00009114 April 2023


  1. Frampton GM et al. Nat Biotechnol 2013;31:1023–1031.
  2. Milbury CA et al. PLoS One. 2022;17(3):e0264138.
  3. Drilon A et al. Clin Cancer Res 2015;21:3631–3639.
  4. Rankin A et al. Oncologist 2016;21:1306–1314.
  5. Ross JS et al. Cancer 2016;122:2654–2662.
  6. Suh JH et al. Oncologist 2016;21:684–691.
  7. Hirshfield KM et al. Oncologist 2016;21:1315–1325.
  8. Woodhouse R, et al. PLoS One. 2020;15:e-237802.
  9. He et al. Blood 2016;127(24):3004-3014.
  10. FoundationOne® CDx Technical Specifications.
  11. FoundationOne® Liquid CDx Technical Specifications.
  12. FoundationCore®. FoundationInsights™. Available at https://www.foundationmedicine.com/insights-and-trials/foundation-insights.